Large Insider Purchases
Institutional-Scale SEC Form 4 Buy Signals
The Signal of $1M+ Conviction
When a corporate executive invests more than $1,000,000 of their own capital into company shares, it represents the highest level of conviction. These seven-figure purchases reflect management's belief in the company's future value.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-02 01:58 | 2024-01-30 | VERA | Vera Therapeutics, Inc. | Katabi Maha | Director | Pharmaceutical Preparations | BUY | $31.00 | 161,290 | $4,999,990 | 3,628,446 | +4.7% |
| 2024-02-02 00:47 | 2024-01-30 | AVBP | ArriVent BioPharma, Inc. | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10% owner | Pharmaceutical Preparations | BUY | $18.00 | 555,555 | $9,999,990 | 4,484,672 | +14.1% |
| 2024-02-02 00:56 | 2024-01-31 | ECAT | BlackRock ESG Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $16.48 | 72,663 | $1,197,414 | 25,552,965 | +0.3% |
| 2024-02-02 00:54 | 2024-01-31 | BMEZ | BlackRock Health Sciences Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.53 | 170,288 | $2,643,755 | 18,542,630 | +0.9% |
| 2024-02-02 00:51 | 2024-01-31 | BIGZ | BlackRock Technology & Private Equity Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $7.64 | 427,771 | $3,269,924 | 46,708,288 | +0.9% |
| 2024-02-02 00:38 | 2024-01-30 | KALV | KalVista Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $14.47 | 88,099 | $1,274,793 | 4,738,683 | +1.9% |
| 2024-02-02 04:57 | 2024-01-30 | LSXMK | Liberty Media Corp | BERKSHIRE HATHAWAY INC | 10% owner | Television Broadcasting Stations | BUY | $30.30 | 1,028,053 | $31,150,314 | 48,499,472 | +2.2% |
| 2024-02-02 04:56 | 2024-01-30 | LSXMA | Liberty Media Corp | BERKSHIRE HATHAWAY INC | 10% owner | Television Broadcasting Stations | BUY | $30.37 | 799,629 | $24,288,411 | 23,740,032 | +3.5% |
| 2024-02-01 00:30 | 2024-01-29 | CGON | CG Oncology, Inc. | Song Hong Fang | Director | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 263,157 | $4,999,983 | 613,928 | +75.0% |
| 2024-01-31 22:57 | 2024-01-30 | EPSN | Epsilon Energy Ltd. | Stabell Jason | Director, Officer - Chief Executive Officer | Crude Petroleum & Natural Gas | BUY | $4.82 | 245,200 | $1,181,864 | 324,734 | +308.3% |
| 2024-02-01 01:00 | 2024-01-29 | RCUS | Arcus Biosciences, Inc. | GILEAD SCIENCES, INC. | 10% owner | Pharmaceutical Preparations | BUY | $21.00 | 15,238,095 | $319,999,995 | 30,061,124 | +102.8% |
| 2024-01-31 19:45 | 2024-01-29 | ECAT | BlackRock ESG Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $16.80 | 140,097 | $2,353,630 | 25,480,302 | +0.6% |
| 2024-01-31 19:26 | 2024-01-29 | BMEZ | BlackRock Health Sciences Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.42 | 323,445 | $4,989,042 | 18,372,342 | +1.8% |
| 2024-01-31 19:24 | 2024-01-29 | BIGZ | BlackRock Technology & Private Equity Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $7.67 | 408,524 | $3,132,889 | 46,280,517 | +0.9% |
| 2024-01-31 19:22 | 2024-01-29 | BCAT | BlackRock Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.43 | 87,639 | $1,352,655 | 14,467,972 | +0.6% |
| 2024-02-01 00:17 | 2024-01-29 | CGON | CG Oncology, Inc. | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 400,000 | $7,600,000 | 400,000 | +100.0% |
| 2024-02-01 00:11 | 2024-01-30 | AVBP | ArriVent BioPharma, Inc. | GORDON CARL L | Director, 10% owner | Pharmaceutical Preparations | BUY | $18.00 | 444,444 | $7,999,992 | 1,513,664 | +41.6% |
| 2024-02-01 00:10 | 2024-01-30 | AVBP | ArriVent BioPharma, Inc. | HEALY JAMES | Director | Pharmaceutical Preparations | BUY | $18.00 | 444,444 | $7,999,992 | 1,696,752 | +35.5% |
| 2024-02-01 00:26 | 2024-01-29 | TRML | N/A | MCDADE MARK | Director | Other | BUY | $32.50 | 100,000 | $3,250,000 | 448,431 | +28.7% |
| 2024-02-01 00:12 | 2024-01-30 | AVBP | ArriVent BioPharma, Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | Pharmaceutical Preparations | BUY | $18.00 | 444,444 | $7,999,992 | 1,513,664 | +41.6% |
| 2024-01-31 00:23 | 2024-01-26 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cormorant Asset Management, LP | 10% owner | Pharmaceutical Preparations | BUY | $32.24 | 282,632 | $9,111,943 | 725,000 | +63.9% |
| 2024-01-31 00:39 | 2023-12-07 | WVE | Wave Life Sciences Ltd. | GSK plc | 10% owner | Pharmaceutical Preparations | BUY | $5.00 | 3,300,000 | $16,500,000 | 13,983,761 | +30.9% |
| 2024-01-29 22:43 | 2024-01-29 | NCDL | Nuveen Churchill Direct Lending Corp. | TEACHERS INSURANCE & ANNUITY ASSOCIATION OF AMERICA | 10% owner | Other | BUY | $18.05 | 1,662,050 | $30,000,003 | 6,810,466 | +32.3% |
| 2024-01-30 03:07 | 2024-01-25 | KALV | KalVista Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $14.05 | 91,804 | $1,289,800 | 4,650,584 | +2.0% |
| 2024-01-27 01:10 | 2024-01-25 | ECAT | BlackRock ESG Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $16.67 | 406,885 | $6,784,645 | 25,340,205 | +1.6% |
| 2024-01-27 01:07 | 2024-01-25 | BMEZ | BlackRock Health Sciences Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.22 | 553,880 | $8,431,604 | 18,048,897 | +3.2% |
| 2024-01-27 01:04 | 2024-01-25 | BIGZ | BlackRock Technology & Private Equity Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $7.55 | 862,110 | $6,511,431 | 45,871,993 | +1.9% |
| 2024-01-27 03:13 | 2024-01-25 | ACET | Adicet Bio, Inc. | GORDON CARL L | Director, 10% owner | Pharmaceutical Preparations | BUY | $2.40 | 3,125,000 | $7,500,000 | 1,255,985 | +100.0% |
| 2024-01-27 01:40 | 2024-01-24 | CODI | Compass Diversified Holdings | SABO ELIAS | Other | Household Furniture | BUY | $22.62 | 90,000 | $2,035,818 | 675,549 | +15.4% |
| 2024-01-27 02:18 | 2024-01-24 | PFLEX | PIMCO Flexible Credit Income Fund Class A-4 | IVASCYN DANIEL J | Other | Other | BUY | $6.87 | 291,121 | $2,000,000 | 1,255,575 | +30.2% |
| 2024-01-27 03:14 | 2024-01-25 | ACET | Adicet Bio, Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | Pharmaceutical Preparations | BUY | $2.40 | 3,125,000 | $7,500,000 | 1,255,985 | +100.0% |
| 2024-01-25 22:18 | 2024-01-23 | N/A | N/A | Abu Dhabi Investment Authority | 10% owner | Other | BUY | $1,835.83 | 13,618 | $25,000,000 | 43,576 | +45.5% |
| 2024-01-25 22:14 | 2024-01-23 | N/A | N/A | Abu Dhabi Investment Authority | 10% owner | Other | BUY | $14.74 | 1,492,436 | $22,000,000 | 9,888,085 | +17.8% |
| 2024-01-26 00:32 | 2024-01-23 | EWTX | Edgewise Therapeutics, Inc. | Thompson Peter A. | Director, 10% owner | Pharmaceutical Preparations | BUY | $11.00 | 454,545 | $4,999,995 | 14,436,497 | +3.3% |
| 2024-01-26 04:00 | 2024-01-23 | CALC | CalciMedica, Inc. | Sanderling Venture Partners VI LP | 10% owner | Pharmaceutical Preparations | BUY | $3.70 | 679,384 | $2,515,080 | 30,292 | +100.0% |
| 2024-01-26 04:00 | 2024-01-23 | CALC | CalciMedica, Inc. | MIDDLETON FRED A | Director, 10% owner | Pharmaceutical Preparations | BUY | $3.70 | 679,384 | $2,515,080 | 30,292 | +100.0% |
| 2024-01-26 05:25 | 2024-01-23 | LSXMK | Liberty Media Corp | BERKSHIRE HATHAWAY INC | 10% owner | Television Broadcasting Stations | BUY | $30.97 | 1,002,741 | $31,057,596 | 47,471,419 | +2.2% |
| 2024-01-26 05:25 | 2024-01-23 | LSXMA | Liberty Media Corp | BERKSHIRE HATHAWAY INC | 10% owner | Television Broadcasting Stations | BUY | $30.99 | 438,945 | $13,602,291 | 22,940,403 | +2.0% |
| 2024-01-26 00:28 | 2024-01-23 | EWTX | Edgewise Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | Pharmaceutical Preparations | BUY | $11.00 | 454,545 | $4,999,995 | 14,436,497 | +3.3% |
| 2024-01-25 02:44 | 2024-01-22 | VRDN | Viridian Therapeutics, Inc.\DE | Fairmount Funds Management LLC | Director, 10% owner, Other | Pharmaceutical Preparations | BUY | $21.00 | 476,190 | $9,999,990 | 1,839,954 | +34.9% |
| 2024-01-25 03:02 | 2024-01-23 | ECAT | BlackRock ESG Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $16.52 | 217,360 | $3,590,961 | 24,933,320 | +0.9% |
| 2024-01-25 02:59 | 2024-01-23 | BMEZ | BlackRock Health Sciences Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.10 | 156,680 | $2,366,228 | 17,495,017 | +0.9% |
| 2024-01-25 02:57 | 2024-01-23 | BIGZ | BlackRock Technology & Private Equity Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $7.46 | 546,429 | $4,073,683 | 45,009,883 | +1.2% |
| 2024-01-25 02:55 | 2024-01-23 | BCAT | BlackRock Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.25 | 134,975 | $2,057,923 | 14,333,330 | +1.0% |
| 2024-01-25 04:24 | 2024-01-22 | KALV | KalVista Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $12.53 | 99,129 | $1,241,680 | 4,558,780 | +2.2% |
| 2024-01-23 18:30 | 2024-01-19 | BMEZ | BlackRock Health Sciences Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $14.98 | 173,975 | $2,605,728 | 17,338,337 | +1.0% |
| 2024-01-23 18:28 | 2024-01-19 | BIGZ | BlackRock Technology & Private Equity Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $7.30 | 346,839 | $2,533,243 | 44,463,454 | +0.8% |
| 2024-01-23 18:26 | 2024-01-19 | BCAT | BlackRock Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% owner | Other | BUY | $15.08 | 325,473 | $4,909,630 | 14,198,355 | +2.3% |
| 2024-01-24 02:41 | 2024-01-19 | NN | NEXTNAV INC. | SAMBERG JOSEPH D | 10% owner | Search, Detection, Navigation, Guidance, Aeronautical Sys | BUY | $3.91 | 300,000 | $1,172,760 | 9,500,000 | +3.3% |
| 2024-01-23 01:06 | 2024-01-18 | THM | INTERNATIONAL TOWER HILL MINES LTD | PAULSON & CO. INC. | 10% owner | Metal Mining | BUY | $0.66 | 2,268,256 | $1,506,122 | 64,198,980 | +3.7% |
Institutional Conviction in Form 4
Tracking these institutional-scale purchases allows you to follow the "smart money" when their conviction is highest. When an executive or a 10% beneficial owner commits a seven-figure sum to an open-market transaction, it bypasses the routine noise of stock-based compensation. These trades are often a precursor to major corporate developments or a signal that management views the current market valuation as significantly disconnected from the company’s internal growth trajectory. By monitoring these high-value entries, investors can align their portfolios with the capital of those who possess the most intimate understanding of a business's long-term health and potential.
Filtering the Market Noise
Our platform is designed to eliminate the noise and focus strictly on high-impact accumulation from directors and CEOs betting big on their company’s future. The SEC EDGAR database is frequently flooded with thousands of automated Form 4 filings, many of which involve small, technical, or pre-scheduled trades that offer little predictive value for the average investor. By applying a strict $1,000,000 minimum threshold, we isolate the transactions where insiders are taking substantial personal financial risk. This high-conviction filter serves as a powerful transparency tool, identifying the exact moments when corporate leadership moves away from passive ownership toward aggressive capital deployment.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.